Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 5th Floor 36 Dame Street, Dublin 2, Ireland

InjectCOVID19intomybrain Jul. 15 at 8:11 PM

$AMRN the SHIT slide is already begun and the BAGHOLDERS are clueless. By this time next month we’ll be back to single digits. As the old saying goes SHIT may float for a little bit but eventually it sinks to the MURKY depths below never to rise again. It’s only a matter of time

0 · Reply

PotatoSalad Jul. 15 at 7:11 PM

$AMRN EU sold for pennies, coupons in the US, halving the script prices to not get destroyed by generics.

1 · Reply

RunningQuarters Jul. 15 at 6:51 PM

$AMRN just got 3 mos. of Vascepa for 185.14. Wow. Cheapest I've ever gotten it since going on Medicare and ChampVA.

1 · Reply

declanaidan Jul. 15 at 6:29 PM

$AMRN We're in summer doldrums with AMRN now, at least up to next earnings report in 2-3 weeks. That report cc should shed very significant, substanitive light on path forward. Meanwhile, we hold, maybe add slightly to our nice YTD gain of close to 70%. Darling NVDA getting lots of love today, even so, still only up around 25% YTD.

2 · Reply

VascepaBID Jul. 15 at 5:57 PM

$AMRN Vascepa brand scripts increased dramatically in my pharmacy ... but what is the plan for the US? Literally all they did was take a break to restart again in the US? Seems like wasted time to me

2 · Reply

ians Jul. 15 at 3:18 PM

$AMRN Zacks says 6-12mo runway to Outperform. ☘️💎 Let’s get that $120 PT(from yours truly 😉) https://finance.yahoo.com/news/zacks-approach-beat-markets-amarin-130600008.html

0 · Reply

Kevinthekid1984 Jul. 15 at 12:56 PM

$AMRN $SPY new all time highs in crypto AND the stock market. I told you

0 · Reply

DoMoreCharity Jul. 15 at 11:18 AM

$AMRN https://www.mdpi.com/2072-6643/17/14/2322

0 · Reply

Bulltrader988 Jul. 15 at 5:42 AM

$AMRN still sniffing this 👃👀

1 · Reply

SaltyNuts Jul. 15 at 4:49 AM

$AMRN down 87.89% over the past 5 years and you guys are praying for a miracle that's not coming.

1 · Reply

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

May 7, 2025, 11:01 AM EDT - 2 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:15 PM EDT - 2 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 2 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 14, 2025, 10:02 AM EDT - 3 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Apr 9, 2025, 7:30 AM EDT - 3 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 3 months ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 4 months ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 4 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 12, 2025, 10:30 AM EDT - 4 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:00 AM EST - 4 months ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 5 months ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 7 months ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 7 months ago

Amarin Appoints Peter Fishman Chief Financial Officer

Nov 19, 2024, 7:52 AM EST - 8 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Oct 30, 2024, 8:50 PM EDT - 9 months ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Sep 9, 2024, 7:30 AM EDT - 11 months ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 11 months ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 1 year ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 10:43 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 1 year ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 10:18 AM EST - 1 year ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:00 AM EST - 1 year ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 8:00 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Jan 22, 2024, 7:30 AM EST - 1 year ago

Amarin Chairman & CEO Issue Letter to Shareholders

Jan 15, 2024, 3:06 AM EST - 1 year ago

Amarin: Sarissa Is Giving Me Hope Again

Jan 10, 2024, 6:40 PM EST - 1 year ago

Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

Jan 10, 2024, 7:00 AM EST - 1 year ago

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Dec 11, 2023, 8:00 AM EST - 1 year ago

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 4, 2023, 4:23 PM EST - 1 year ago

Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership

Nov 12, 2023, 9:00 AM EST - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

Nov 1, 2023, 10:40 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q3 2023 Earnings Call Transcript

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Amarin Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 12:00 PM EDT - 1 year ago

Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

Oct 26, 2023, 8:00 AM EDT - 1 year ago

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

InjectCOVID19intomybrain Jul. 15 at 8:11 PM

0 · Reply

PotatoSalad Jul. 15 at 7:11 PM

$AMRN EU sold for pennies, coupons in the US, halving the script prices to not get destroyed by generics.

1 · Reply

RunningQuarters Jul. 15 at 6:51 PM

$AMRN just got 3 mos. of Vascepa for 185.14. Wow. Cheapest I've ever gotten it since going on Medicare and ChampVA.

1 · Reply

declanaidan Jul. 15 at 6:29 PM

2 · Reply

VascepaBID Jul. 15 at 5:57 PM

$AMRN Vascepa brand scripts increased dramatically in my pharmacy ... but what is the plan for the US? Literally all they did was take a break to restart again in the US? Seems like wasted time to me

2 · Reply

ians Jul. 15 at 3:18 PM

$AMRN Zacks says 6-12mo runway to Outperform. ☘️💎 Let’s get that $120 PT(from yours truly 😉) https://finance.yahoo.com/news/zacks-approach-beat-markets-amarin-130600008.html

0 · Reply

Kevinthekid1984 Jul. 15 at 12:56 PM

$AMRN $SPY new all time highs in crypto AND the stock market. I told you

0 · Reply

DoMoreCharity Jul. 15 at 11:18 AM

$AMRN https://www.mdpi.com/2072-6643/17/14/2322

0 · Reply

Bulltrader988 Jul. 15 at 5:42 AM

$AMRN still sniffing this 👃👀

1 · Reply

SaltyNuts Jul. 15 at 4:49 AM

$AMRN down 87.89% over the past 5 years and you guys are praying for a miracle that's not coming.

1 · Reply

SaltyNuts Jul. 15 at 4:41 AM

$AMRN How far down do you guys think this is going to be tomorrow? Will it close under $15 or is that going to take a couple of more days?

1 · Reply

DoMoreCharity Jul. 15 at 12:31 AM

$AMRN https://onlinelibrary.wiley.com/doi/10.1111/dme.70030

0 · Reply

Flyfishingstocks Jul. 14 at 10:30 PM

$AMRN A chart of irony...

4 · Reply

declanaidan Jul. 14 at 8:44 PM

$AMRN Tried mightingly to drive this down today with target in mid 15's Admittedly pps vulnerable after straight up run up last three months, but pps resilient and still closed in 16's.

3 · Reply

hodlingisforlosers Jul. 14 at 7:53 PM

$AMRN every big dip here lately led to bigger rip bears are losing control started here with low 16s looking at $19 exit yum

0 · Reply

Novo1 Jul. 14 at 7:31 PM

$AMRN if you’re waiting for 50, it’s going to be a while! Given the direction of Amarin’s stock, more likely to see zero before fifty!!😱

2 · Reply

MoneyInc Jul. 14 at 7:23 PM

$AMRN averaged up today with another 2300 shares. Here for $50+

1 · Reply

VascepaGivesBoners Jul. 14 at 5:10 PM

$AMRN we prob going to test the SMA20 15.50s ish. Need a nice bounce off that for the next leg up I think.

3 · Reply

SaltyNuts Jul. 14 at 4:53 PM

$AMRN Can we get under $14 by Friday?

2 · Reply

Flyfishingstocks Jul. 14 at 4:38 PM

$AMRN Bears are eating this failure to follow through

1 · Reply

bennfine Jul. 14 at 4:33 PM

$AMRN Someone please remind me why I am not in RKLB and HOOD and instead in this thing.......ugh what a day.

1 · Reply

HamarinU2 Jul. 14 at 3:20 PM

$AMRN Twinkie the kid and Mike Brady are our newest keyboard warriors. Always fun to see kids show up and use their Happy Meal money for the week and buy a few shares and make a stand

1 · Reply

Market Cap	350.57M
Revenue (ttm)	228.61M
Net Income (ttm)	-82.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-35.95%
Debt to Equity Ratio	0.00

Volume	84,283
Avg Vol	126,786
Day's Range	N/A - N/A
Shares Out	20.71M
Stochastic %K	19%
Beta	0.82
Analysts	Buy
Price Target	$10.50